Search hospitals
>
Illinois
>
Springfield
Southern Illinois University School of Medicine
Claim this profile
Springfield, Illinois 62702
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Brain Tumor
Conducts research for Neuroblastoma
585 reported clinical trials
11 medical researchers
Summary
Southern Illinois University School of Medicine is a medical facility located in Springfield, Illinois. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Brain Tumor, Neuroblastoma and other specialties. Southern Illinois University School of Medicine is involved with conducting 585 clinical trials across 788 conditions. There are 11 research doctors associated with this hospital, such as Bryan A. Faller, Gregory P. Brandt, James L. Wade, and Jeffrey Bennett, MD.
Area of expertise
Cancer
Southern Illinois University School of Medicine has run 80 trials for Cancer. Some of their research focus areas include:
Lung Cancer
Southern Illinois University School of Medicine has run 63 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Bryan A. Faller
Crossroads Cancer Center
7 years of reported clinical research
Gregory P. Brandt
Southern Illinois University School of Medicine
8 years of reported clinical research
James L. Wade
Decatur Memorial Hospital
4 years of reported clinical research
Jeffrey Bennett, MD
Southern Illinois University School of Medicine
6 years of reported clinical research
Clinical Trials running at Southern Illinois University School of Medicine
Lung Cancer
Prostate Cancer
Breast Cancer
Breast cancer
Cancer
Kidney Cancer
Pancreatic Cancer
Esophageal cancer
Ovarian Cancer
Multiple Myeloma
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Southern Illinois University School of Medicine?
Southern Illinois University School of Medicine is a medical facility located in Springfield, Illinois. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Brain Tumor, Neuroblastoma and other specialties. Southern Illinois University School of Medicine is involved with conducting 585 clinical trials across 788 conditions. There are 11 research doctors associated with this hospital, such as Bryan A. Faller, Gregory P. Brandt, James L. Wade, and Jeffrey Bennett, MD.
Where is Southern Illinois University School of Medicine located?
The Southern Illinois University School of Medicine hospital is located at 327 W Calhoun Ave, Springfield, IL 62702, near the intersection of N 1st St and W Calhoun Ave. It is approximately 1 mile north of downtown Springfield.
Who should I call to ask about financial aid or insurance network?
**Southern Illinois University School of Medicine Contact Information:** - **Financial Assistance:** For inquiries, contact the SIU Medicine Billing and Insurance Department. Specific contact details are not provided online. - **Insurance Matters:** - Life Insurance: Securian Financial/Minnesota Life at 888/202-5525. - Employee Assistance Program: Magellan Behavioral Health. - **General Financial Inquiries:** Contact the Bursar's Office for tuition and fee payments at (618) 453-2221 (option one) or via SalukiNet for online payments. - **Financial Aid:** Reach out to the Financial Aid Office at 217-545-2860 or financialaid@siumed.edu for assistance with financial aid packages, debt counseling, and short-term emergency loans.
What insurance does Southern Illinois University School of Medicine accept?
The Southern Illinois University School of Medicine mandates the SIUC Student Health Insurance Plan for students enrolled in on-campus courses. This comprehensive plan covers pharmaceuticals, immunizations, emergency room visits, hospitalizations, surgeries, ambulance services, and specialty care, complementing the services provided by the Student Health Center. Students with comparable health insurance coverage may opt out and receive a refund.
What awards or recognition has Southern Illinois University School of Medicine received?
Southern Illinois University School of Medicine in Springfield, Illinois, has been awarded $28.4 million in grants for research, training, and service in fiscal year 2023, marking a significant increase of over 20% from the previous year. The institution's research spans multiple disciplines such as invasive species control, wildlife disease surveillance, human health, advanced communications, and environmental concerns. Furthermore, the introduction of the Research Scholars Program acknowledges the research achievements of medical students.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.